Clinical Trial Update: Managed Access Programs for LEE011, Ribociclib

View source ↗

Summary

Clinical trial update announcing managed access programs for ribociclib (LEE011) in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Status: AVAILABLE